David W. Haas

17.4k total citations
212 papers, 8.7k citations indexed

About

David W. Haas is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, David W. Haas has authored 212 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Infectious Diseases, 107 papers in Virology and 47 papers in Epidemiology. Recurrent topics in David W. Haas's work include HIV/AIDS drug development and treatment (111 papers), HIV Research and Treatment (106 papers) and HIV/AIDS Research and Interventions (52 papers). David W. Haas is often cited by papers focused on HIV/AIDS drug development and treatment (111 papers), HIV Research and Treatment (106 papers) and HIV/AIDS Research and Interventions (52 papers). David W. Haas collaborates with scholars based in United States, South Africa and United Kingdom. David W. Haas's co-authors include Todd Hulgan, Edward P. Acosta, David B. Clifford, Renata Forste, G. Wilkinson, Richard B. Kim, Heather J. Ribaudo, Marylyn D. Ritchie, Roy M. Gulick and Derya Unutmaz and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

David W. Haas

205 papers receiving 8.4k citations

Peers

Countries citing papers authored by David W. Haas

Since Specialization

Citations

This map shows the geographic impact of David W. Haas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Haas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Haas more than expected).

Fields of papers citing papers by David W. Haas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David W. Haas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Haas. The network helps show where David W. Haas may publish in the future.

Co-authorship network of co-authors of David W. Haas

This figure shows the co-authorship network connecting the top 25 collaborators of David W. Haas. A scholar is included among the top collaborators of David W. Haas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David W. Haas. David W. Haas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa 2024 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), Roeland E. Wasmann, Godspower Akpomiemie, Nomathemba Chandiwana, Simiso Sokhela, Michelle Moorhouse, François Venter, Paolo Denti, Lubbe Wiesner, Frank A. Post, David W. Haas, Gary Maartens, Phumla Sinxadi	1
2	Impact of HLA class I functional divergence on HIV control 2024 ·Science ·Mathias Viard, Colm Ó’hUigín, Yuko Yuki, Arman Bashirova, David R. Collins, Jonathan M. Urbach, Steven M. Wolinsky, Susan Buchbinder, Gregory D. Kirk, James J. Goedert, Nelson L. Michael, David W. Haas, Steven G. Deeks, Bruce D. Walker, Xu G. Yu, Mary Carrington	6
3	Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus 2022 ·The Journal of Infectious Diseases ·(unknown), (unknown), Gary Maartens, Yuki Bradford, François Venter, Simiso Sokhela, Nomathemba Chandiwana, Roeland E. Wasmann, Paolo Denti, Lubbe Wiesner, Marylyn D. Ritchie, David W. Haas, Phumla Sinxadi	8
4	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa 2022 ·The Journal of Infectious Diseases ·David W. Haas, (unknown), (unknown), (unknown), Gary Maartens, Yuki Bradford, Marylyn D. Ritchie, Sean Wasserman, Graeme Meintjes, Karen Beeri, Neel R. Gandhi, Elin M. Svensson, Paolo Denti, James C.M. Brust	13
5	Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population 2022 ·Journal of Antimicrobial Chemotherapy ·Rulan Griesel, Phumla Sinxadi, (unknown), John A. Joska, Simiso Sokhela, Godspower Akpomiemie, François Venter, Paolo Denti, David W. Haas, Gary Maartens	4
6	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy 2019 ·PMC ·Zeruesenay Desta, Roseann S. Gammal, Li Gong, Michelle Whirl‐Carrillo, Aditya H. Gaur, Chonlaphat Sukasem, Jennifer Hockings, Alan L. Myers, Marelize Swart, Rachel F. Tyndale, Collen Masimirembwa, Otito F. Iwuchukwu, Sanika Chirwa, Jeffrey L. Lennox, Andrea Gaedigk, Teri E. Klein, David W. Haas	19
7	Mitochondrial DNA Haplogroups and Frailty in Adults Living with HIV 2019 ·AIDS Research and Human Retroviruses ·Kristine M. Erlandson, Yuki Bradford, David C. Samuels, Todd T. Brown, Jing Sun, Kunling Wu, Katherine Tassiopoulos, Marylyn D. Ritchie, David W. Haas, Todd Hulgan, (unknown)	8
8	Hemochromatosis ( HFE ) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy 2018 ·AIDS Research and Human Retroviruses ·Asha Kallianpur, Mariana Gerschenson, Todd Hulgan, Harpreet Kaur, David B. Clifford, David W. Haas, Deborah G. Murdock, Justin C. McArthur, David C. Samuels, David M. Simpson	4
9	Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives 2017 ·The Lancet Infectious Diseases ·Laurent Abel, Jacques Fellay, David W. Haas, Erwin Schurr, Geetha Srikrishna, Michael E. Urbanowski, Nimisha Chaturvedi, Sudha Srinivasan, Daniel Johnson, William R. Bishai	83
10	Teaching Retropubic Midurethral Sling Procedure on a Surgical Simulation Model 2013 ·Neurourology and Urodynamics ·(unknown), Patrick J. Woodman, (unknown), (unknown), David W. Haas, Mary Pell Abernathy, Lee A. Learman	1
11	Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans 2012 ·Human Molecular Genetics ·Paul J. McLaren, Stephan Ripke, Kimberly Pelak, Amy Weintrob, Nikolaos A. Patsopoulos, Xiaoming Jia, Rachel Erlich, Niall J. Lennon, Carl Kadie, David Heckerman, Namrata Gupta, David W. Haas, Steven G. Deeks, Florencia Pereyra, Bruce D. Walker, Paul I.W. de Bakker	44
12	Life cycle assessment of the Gold Coast urban water system 2011 ·Water ·David W. Haas, Joe Lane, Paul Lant	5
13	Mitochondrial Genomics and CD4 T-Cell Count Recovery After Antiretroviral Therapy Initiation in AIDS Clinical Trials Group Study 384 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), David C. Samuels, Gregory K. Robbins, (unknown), Jeffrey A. Canter, Richard B. Pollard, David W. Haas, Robert W. Shafer, Spyros A. Kalams, Deborah G. Murdock, Marylyn D. Ritchie, Todd Hulgan	17
14	Reply to Tong et al. 2006 ·Clinical Infectious Diseases ·Heather J. Ribaudo, David W. Haas, Edward P. Acosta	24
15	Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study 2006 ·Clinical Infectious Diseases ·Heather J. Ribaudo, David W. Haas, C. Tierney, Richard B. Kim, G. Wilkinson, Roy M. Gulick, David B. Clifford, Catia Marzolini, Courtney V. Fletcher, Karen T. Tashima, Daniel R. Kuritzkes, Edward P. Acosta	170
16	Will pharmacogenomic discoveries improve HIV therapeutics? 2005 ·PubMed ·David W. Haas	14
17	MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·David W. Haas, Hulin Wu, Haihong Li, Ronald J. Bosch, Michael M. Lederman, Daniel R. Kuritzkes, Alan Landay, Elizabeth Connick, Constance A. Benson, G. Wilkinson, Harold A. Kessler, Richard B. Kim	49
18	Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase 2000 ·AIDS ·Michael M. Lederman, Ray A. McKinnis, Dennis Kelleher, Amy Cutrell, John W. Mellors, (unknown), Elizabeth Cooney, David W. Haas, Richard Haubrich, James Stanford, James Horton, Alan Landay, William Spreen	69
19	Sequential Indium-Labeled Leukocyte and Bone Scans to Diagnose Prosthetic Joint Infection 2000 ·Clinical Orthopaedics and Related Research ·(unknown), Michael Christie, William R. Martin, (unknown), David W. Haas	62
20	Treatment of Gram-positive Nosocomial Pneumonia: Prospective Randomized Comparison of Quinupristin/Dalfopristin versus Vancomycin 2000 ·American Journal of Respiratory and Critical Care Medicine ·J.-Y. Fagon, (unknown), David W. Haas, Antoní Torres, Claude Gibert, William G. Cheadle, Robert E. Falcone, James D. Anholm, Fabrice Paganin, Timothy C. Fabian, (unknown)	169

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact